SOURCE: Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc.

September 04, 2013 09:00 ET

Plandai Biotechnology, Inc. Announces Completion of Production Facility, Installation of Equipment to Commence

SEATTLE, WA--(Marketwired - Sep 4, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today provided updated information on the status of the Company's operations, specifically addressing the manufacturing facility in South Africa, status of clinical trials, and expectation for commencing sales.

Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, stated, "As a company, we're excited to announce that our subsidiary, Green Gold Biotechnologies, has completed its state-of-the-art production facility in Mpumalanga, South Africa, in the heart of our tea estate. The unique processing and extraction system we employ to ensure that our products are highly bioavailable requires that we use only live plant material. We are therefore constrained to have our factory onsite, enabling processing to commence within an hour of harvest. The 10,000m2 building is now complete, the equipment has arrived, and installation will commence in the coming weeks.

"The green tea, which will comprise the first of our extracts brought to market, is just coming out of its dormant season. We will shortly fertilize and then allow the tea bushes to reestablish the high levels of polyphenols, before commercial production commences. Once the facility is operational, we will begin running test batches through the system, comparing the results to our original product profiles to guarantee consistency of quality before full-scale production can take place. Our timeline is to have Phytofare™ Catechin Complex production ready by year end with our citrus-based Limonoid Glycoside Complex available summer 2014."

Commenting on when Phytofare™ Pheroid™ ("ph2") product will reach the market, Mr. Duffield added, "Once we realized that we had the incredible opportunity to obtain a license to use the Pheroid™ technology developed by North West University, we grasped the benefit this would have on our Phytofare™ products. We are projecting to begin validating finished ph2™ Catechin Complex products in liquid, gel capsule, and topical cream, by early 2014, with product available to market before March 2014.

"We believe that the combination of these technologies will usher in a new era of botanical drug innovation and possibility. This is an amazing time for Plandaí as we near the end of more than decade of product development. We are blessed to have favorable test results coupled with overwhelming consumer enthusiasm as we approach the imminent market release of the first of many new products."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact Information